Zacks Research Analysts Reduce Earnings Estimates for Neogen

Neogen Co. (NASDAQ:NEOG) – Equities researchers at Zacks Research dropped their Q3 2025 EPS estimates for shares of Neogen in a note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.12 per share for the quarter, down from their previous forecast of $0.14. The consensus estimate for Neogen’s current full-year earnings is $0.41 per share. Zacks Research also issued estimates for Neogen’s Q4 2025 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.52 EPS.

NEOG has been the subject of a number of other research reports. Piper Sandler restated a “neutral” rating and issued a $13.00 price target (down previously from $16.50) on shares of Neogen in a research note on Tuesday, January 21st. Guggenheim began coverage on shares of Neogen in a research report on Thursday, December 19th. They issued a “buy” rating and a $15.00 target price for the company.

Neogen Price Performance

NEOG stock opened at $11.48 on Thursday. The company has a market capitalization of $2.49 billion, a PE ratio of -5.24 and a beta of 1.23. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The stock’s 50 day moving average is $12.52 and its two-hundred day moving average is $14.71. Neogen has a 52-week low of $10.72 and a 52-week high of $18.58.

Neogen (NASDAQ:NEOG) last announced its earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. The business had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.11 earnings per share.

Hedge Funds Weigh In On Neogen

Institutional investors have recently modified their holdings of the company. Citigroup Inc. grew its position in Neogen by 129.1% in the 3rd quarter. Citigroup Inc. now owns 231,833 shares of the company’s stock worth $3,897,000 after purchasing an additional 130,641 shares during the last quarter. American Capital Management Inc. grew its holdings in Neogen by 36.5% in the 3rd quarter. American Capital Management Inc. now owns 3,414,700 shares of the company’s stock worth $57,401,000 after buying an additional 913,604 shares in the last quarter. State Street Corp grew its stake in shares of Neogen by 3.1% in the third quarter. State Street Corp now owns 7,932,192 shares of the company’s stock worth $133,340,000 after purchasing an additional 236,762 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Neogen by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 38,166 shares of the company’s stock valued at $642,000 after buying an additional 5,804 shares during the period. Finally, Barclays PLC raised its position in shares of Neogen by 129.8% during the 3rd quarter. Barclays PLC now owns 366,753 shares of the company’s stock worth $6,165,000 after buying an additional 207,160 shares in the last quarter. Institutional investors own 96.73% of the company’s stock.

Insider Activity

In other Neogen news, CFO David H. Naemura bought 14,800 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were purchased at an average price of $11.11 per share, with a total value of $164,428.00. Following the completion of the acquisition, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John Edward Adent bought 23,035 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, with a total value of $254,076.05. Following the completion of the acquisition, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at approximately $2,968,878.92. The trade was a 9.36 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.13% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.